These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 17366693)

  • 1. Myeloid Growth Factor Guidelines: moving toward a societal perspective.
    Winn RJ
    J Natl Compr Canc Netw; 2007 Feb; 5(2):117. PubMed ID: 17366693
    [No Abstract]   [Full Text] [Related]  

  • 2. Myeloid growth factors clinical practice guidelines in oncology.
    Crawford J; Althaus B; Armitage J; Blayney DW; Cataland S; Dale DC; Demetri GD; Foran J; Heaney ML; Htoy S; Kloth DD; Lyman GH; Michaud L; Motl S; Vadhan-Raj S; Wong MK;
    J Natl Compr Canc Netw; 2005 Jul; 3(4):540-55. PubMed ID: 16038645
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of American Society of Clinical Oncology guidelines for clinical use of colony-stimulating factors.
    Debrix I; Bouleuc C; Liote H; Milleron B; Beker A
    J Clin Oncol; 1999 Oct; 17(10):3360-1. PubMed ID: 10506640
    [No Abstract]   [Full Text] [Related]  

  • 4. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia.
    Lyman GH; Kuderer NM
    Crit Rev Oncol Hematol; 2004 May; 50(2):129-46. PubMed ID: 15157662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the use of colony-stimulating factors for chemotherapy-induced neutropenia.
    Dale DC
    J Support Oncol; 2005; 3(2 Suppl 1):39-41. PubMed ID: 15794500
    [No Abstract]   [Full Text] [Related]  

  • 6. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.
    Lyman GH; Kleiner JM
    J Natl Compr Canc Netw; 2007 Feb; 5(2):217-28. PubMed ID: 17335690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of prophylactic management of chemotherapy-induced neutropenia.
    Repetto L; Accettura C
    Anticancer Drugs; 2003 Oct; 14(9):725-30. PubMed ID: 14551505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid growth factors: to use or not to use, that is the question.
    Morrison V
    Leuk Lymphoma; 2006 May; 47(5):780-2. PubMed ID: 16753858
    [No Abstract]   [Full Text] [Related]  

  • 9. NCCN guidelines advocate wider use of colony-stimulating factor.
    McNeil C
    J Natl Cancer Inst; 2005 May; 97(10):710-1. PubMed ID: 15900037
    [No Abstract]   [Full Text] [Related]  

  • 10. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.
    Ozer H; Armitage JO; Bennett CL; Crawford J; Demetri GD; Pizzo PA; Schiffer CA; Smith TJ; Somlo G; Wade JC; Wade JL; Winn RJ; Wozniak AJ; Somerfield MR;
    J Clin Oncol; 2000 Oct; 18(20):3558-85. PubMed ID: 11032599
    [No Abstract]   [Full Text] [Related]  

  • 11. Myeloid growth factors. Clinical practice guidelines in oncology.
    Crawford J; Althaus B; Armitage J; Balducci L; Bennett C; Blayney DW; Cataland SR; Dale DC; Demetri GD; Erba HP; Foran J; Freifeld AG; Heaney ML; Htoy S; Kloth DD; Lyman GH; Messersmith WA; Michaud LB; Miyata SC; Robbins A; Tallman MS; Vadhan-Raj S; Westervelt P; Wong MK;
    J Natl Compr Canc Netw; 2007 Feb; 5(2):188-202. PubMed ID: 17335688
    [No Abstract]   [Full Text] [Related]  

  • 12. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.
    Lyman GH; Kleiner JM
    Cancer Treat Res; 2011; 157():145-65. PubMed ID: 21052955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colony-stimulating factors in the management of neutropenia and its complications.
    Heuser M; Ganser A
    Ann Hematol; 2005 Oct; 84(11):697-708. PubMed ID: 16047204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence.
    Lyman GH
    J Natl Compr Canc Netw; 2005 Jul; 3(4):557-71. PubMed ID: 16038646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The present and future of G-CSF].
    Solal-Celigny P
    Pathol Biol (Paris); 1989 Nov; 37(9):1014-5. PubMed ID: 2481836
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy.
    Cosler LE; Calhoun EA; Agboola O; Lyman GH
    Pharmacotherapy; 2004 Apr; 24(4):488-94. PubMed ID: 15098803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines.
    Heuser M; Ganser A; Bokemeyer C; ; ;
    Semin Hematol; 2007 Jul; 44(3):148-56. PubMed ID: 17631179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy.
    Daniel DB; Crawford J;
    Curr Hematol Rep; 2005 Nov; 4(6):441-5. PubMed ID: 16232380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemopoietic growth factors in paediatric oncology: a review of the literature.
    Wagner LM; Furman WL
    Paediatr Drugs; 2001; 3(3):195-217. PubMed ID: 11310717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colony-stimulating factors for the management of neutropenia in cancer patients.
    Dale DC
    Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.